Harrow, Inc.

HROW

US4158581094

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harrow, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.45 USD

Average target price

26.65 USD

Spread / Average Target

+155.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARROW, INC.	-6.70%	370M
ELI LILLY AND COMPANY	+24.60%	654B
NOVO NORDISK A/S	+24.08%	552B
JOHNSON & JOHNSON	-5.63%	356B
MERCK & CO., INC.	+15.37%	319B
ABBVIE INC.	+7.38%	295B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	206B
PFIZER, INC.	-9.69%	147B
AMGEN INC.	-6.63%	144B

Other Pharmaceuticals

Market Closed - OTC Markets Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
10.45 ^USD	-3.69%		-17.39%	-6.70%

Apr. 11	Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	MT
Mar. 22	B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	MT

Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
Top Midday Decliners	Mar. 20	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20	CI
Transcript : Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Restore stock falls as weak tech trading drags down annual results	Mar. 14	AN
Harrow, Inc. Announces Board of Director Appointments	Jan. 29	CI
Harrow Health's Eye Treatment Drug Vevye Now Available in US	Jan. 11	MT
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11	CI
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	Jan. 03	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	Jan. 03	MT
Harrow, Inc. Appoints John P. Saharek as President and Chief Executive Officer of its ImprimisRx Division	Jan. 03	CI
Harrow, Inc.(NasdaqGM:HROW) dropped from S&P Pharmaceuticals Select Industry Index	Dec. 18	CI
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application	Nov. 29	CI
Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday	Nov. 14	MT
Top Premarket Decliners	Nov. 14	MT
B. Riley Lowers Harrow's PT to $30 From $45 After Lower-Than-Expected Q3 Results, Reduced Q4 Guidance; Keeps Buy Rating	Nov. 14	MT
Harrow Health Q3 Core Loss Widens, Revenue Rises; Shares Plunge After Hours	Nov. 13	MT
Transcript : Harrow, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Harrow, Inc. Revises Revenue Guidance for the Full Year 2023	Nov. 13	CI
Harrow, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024	Nov. 13	CI